Reopro Ischemic Stroke Trial Halted
This article was originally published in The Pink Sheet Daily
Centocor and Lilly are permanently discontinuing a Phase III study of Reopro (abciximab) for acute ischemic stroke after the study's independent Safety & Efficacy Monitoring Committee confirmed concerns about intracranial hemorrhage that previously prompted the firms to suspend enrollment
You may also be interested in...
Enrollment in the Abciximab in Emergent Stroke Treatment Trial-II was halted due to concerns about the rate of intracranial hemorrhage.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.